Data Presented At Two Global Medical Congresses Reinforce Benefit Of Enbrel® (etanercept) For Patients With Chronic Inflammatory Conditions

Main Category: Arthritis / Rheumatology
Also Included In: Bones / Orthopedics;  Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 31 May 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article




Patient / Public:not yet rated

Healthcare Prof:not yet rated

Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States (U.S.). Eighteen abstracts across four indications, including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe plaque psoriasis (PsO), and psoriatic arthritis (PsA), will be published at two global medical congresses, the European League Against Rheumatism (EULAR) and World Congress of Dermatology (WCD), this week.

Augurex Reports Positive Data For RA Blood Test And Drug Target At The Annual European Congress Of Rheumatology (EULAR)

Main Category: Arthritis / Rheumatology
Also Included In: Blood / Hematology;  Medical Devices / Diagnostics
Article Date: 31 May 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article




Patient / Public:not yet rated

Healthcare Prof:not yet rated

Augurex Life Sciences Corp. reported that in London at the European League Against Rheumatism (EULAR) Conference, leading arthritis researchers presented important data on Augurex’s rheumatoid arthritis (RA) biomarker blood test and novel drug target.

Association Between Financial Conflicts Of Interest And Positive Study Outcomes

Main Category: Clinical Trials / Drug Trials
Also Included In: Pharma Industry / Biotech Industry;  Arthritis / Rheumatology
Article Date: 29 May 2011 – 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article


Patient / Public:not yet rated

Healthcare Prof:not yet rated

Results demonstrate that 91% of RCTs recording this kind of FCOI achieved a positive – outcome, compared to 66.7% of RCTs without specific FCOI (p=0.02) and adjusting for confounding factors did not change this finding.

Is It Ethical To Use Placebo In Rheumatoid Arthritis Clinical Trials?

Main Category: Arthritis / Rheumatology
Also Included In: Clinical Trials / Drug Trials
Article Date: 30 May 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article




Patient / Public:not yet rated

Healthcare Prof:not yet rated

The results of this study, conducted in Germany, re-open the debate on whether it is ethical to conduct placebo-controlled studies where patients in the placebo-group are at a serious disadvantage compared to patients taking the new treatments. The study analysed current study designs, for new therapies such as abatacept (Orencia®), golimumab (Simponi®) or tocilizumab (Actemra®), and showed that patients in the placebo group experienced no change in medication, having to continue with their former, ineffective treatment plus placebo.

New Study Finds That Medicare Beneficiaries With Higher Medical Spending Have Better Health Outcomes

Main Category: Medicare / Medicaid / SCHIP
Also Included In: Public Health
Article Date: 30 May 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article


Advertisement

Patient / Public:not yet rated

Healthcare Prof:not yet rated

A new study from George Mason University and the Urban Institute reveals that greater spending on medical services means better overall health for Medicare participants. Health Administration and Policy Professor Jack Hadley and his co-authors, Urban Institute researchers Timothy Waidmann, Stephen Zuckerman, and Robert Berenson, analyzed data from more than 17,000 Medicare beneficiaries to draw this conclusion.

AACE Applauds Introduction Of House And Senate Bills To Preserve Patient Access To Osteoporosis Testing Under Medicare

Main Category: Bones / Orthopedics
Also Included In: Medicare / Medicaid / SCHIP
Article Date: 30 May 2011 – 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article


Patient / Public:not yet rated

Healthcare Prof:not yet rated

The American Association of Clinical Endocrinologists (AACE) applauds the introduction of legislation in both the U.S. House of Representatives and the U.S. Senate that will preserve patient access to osteoporosis testing and treatment services under the Medicare program.

Survey Reveals HCPs Are Failing To Set Goals With RA Patients

Editor’s Choice
Main Category: Arthritis / Rheumatology
Article Date: 29 May 2011 – 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article


Patient / Public:not yet rated

Healthcare Prof:not yet rated

While the majority of patients with Rheumatoid Arthritis (RA) feel that personalized goal setting would have a positive impact on disease management, many stated that their health care professionals (HCPS) are not discussing approaches to achieving personal or social goals, reports a survey presented at the Annual Meeting of the European League Against Rheumatism (EULAR) in London, May 25-28.

No Overall Increased Cancer Risk Found For Arthritis Patients Taking Newer Treatments

Main Category: Arthritis / Rheumatology
Also Included In: Cancer / Oncology
Article Date: 29 May 2011 – 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article




Patient / Public:not yet rated

Healthcare Prof:not yet rated

Only three percent (n=181) of patients in the study cohort receiving anti-tumour necrosis factor agents (anti-TNFs) for treatment of their arthritis developed a first cancer within nine years and overall risk was not dependent on the type of arthritis.

Spacelabs CardioSens Ultra II Electrodes

Spacelabs CardioSens / Ultra II Electrodes

 

 

 

 

 

 

 

 

Features :

  • Strong, very aggressive adhesive for everyday use and difficult situations
  • Captures ECG signals quickly and easily
  • Extended tab area for quick and easy cable connection
  • Tab shape designed to twist with the cable – not lift electrode from skin
  • Long shelf life – up to 2 years from date of manufacture
  • 500 electrodes per box